Pursuing novel therapeutics targeting NASH with liver fibrosis

Madrigal is a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases. Our most advanced clinical candidate, resmetirom, has the potential to become the first medication approved for the treatment of patients with non-alcoholic steatohepatitis (NASH) with liver fibrosis.

Our Programs - Madrigal Pharmaceuticals OUR PROGRAMS
NASH - Madrigal Pharmaceuticals NASH
About Us - Madrigal Pharmaceuticals ABOUT US

NEWS

May 17, 2022
Madrigal Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences

May 09, 2022
Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 First Quarter Financial Results


PRESS RELEASES >

EVENTS

May 24, 2022
UBS Global Healthcare Conference

May 24, 2022
H.C. Wainwright Global Life Sciences Conference

EVENTS & PRESENTATIONS >

NASH is a growing global health challenge. There are 22 million people living with NASH in the U.S. alone, and more than 8 million who have NASH with significant liver fibrosis.

Learn More